NEW YORK (GenomeWeb News) – Beckman Coulter has completed its $780 million acquisition of Olympus' lab-based diagnostics business, the firm announced over the weekend.
Beckman funded the acquisition with $495 million that was raised through the issuance of two, $250 million senior note offerings, and around $240 million from a common stock offering of approximately 4.7 million shares issued to the public at a price of $53 per share.
The Orange County, Calif.-based diagnostics and life science products firm initially announced the deal in February.
"We are confident that the combination of Olympus diagnostics with our business will provide many cross-selling opportunities — the most compelling being promotion of Beckman Coulter's leading immunoassay products to the loyal base of Olympus' chemistry customers," Scott Garrett, Beckman Coulter's chairman, president, and CEO, said in a statement.